A5066833569- Chronic Lymphocytic Leukemia Research
- Lymphoma Diagnosis and Treatment
- Antibiotic Resistance in Bacteria
- Pediatric Hepatobiliary Diseases and Treatments
- Bacterial biofilms and quorum sensing
- Drug Transport and Resistance Mechanisms
- Asthma and respiratory diseases
- Gut microbiota and health
- Chronic Myeloid Leukemia Treatments
- Intestinal Malrotation and Obstruction Disorders
- Advanced Breast Cancer Therapies
- Vibrio bacteria research studies
- Liver Diseases and Immunity
- Gallbladder and Bile Duct Disorders
- Respiratory and Cough-Related Research
- Yersinia bacterium, plague, ectoparasites research
- Cardiovascular Health and Risk Factors
- Tracheal and airway disorders
- Health and Well-being Studies
- Respiratory Support and Mechanisms
- Diabetes Management and Research
- Antimicrobial Peptides and Activities
- Gastrointestinal Tumor Research and Treatment
- Diabetes, Cardiovascular Risks, and Lipoproteins
- Nosocomial Infections in ICU
AstraZeneca (United States)
2021
University of California, San Francisco
2010-2014
Palo Alto Medical Foundation
2014
Kaiser Permanente Center for Health Research
2013
Bacterial communities in the airways of cystic fibrosis (CF) patients are, as other ecological niches, influenced by autogenic and allogenic factors. However, our understanding microbial colonization younger versus older CF association with pulmonary function is rudimentary at best. Using a phylogenetic microarray, we examine airway microbiota age stratified ranging from neonates (9 months) to adults (72 years). From cohort clinically stable patients, demonstrate that who exhibit poorer...
Primary sclerosing cholangitis (PSC) is frequently associated with pruritus, which significantly impairs quality of life. Maralixibat a selective ileal bile acid transporter (IBAT) inhibitor that lowers circulating (BA) levels and reduces pruritus in cholestatic liver diseases. This the first proof-of-concept study IBAT inhibition PSC.This open-label evaluated safety tolerability maralixibat ≤10 mg/d for 14 weeks adults PSC. Measures biomarkers BA synthesis, cholestasis, function were also...
ABSTRACT Background Alagille syndrome (ALGS) is a multisystem cholestatic disorder. Maralixibat approved for the treatment of pruritus in ALGS with limited data adults. Methods Participants were included if they received ≥ 2 doses maralixibat at age 16 years one three previously published clinical trials. Results Eleven initiated < old (median age, 13.0) median follow‐up 4.1 years. Three participants began old, 3.8 starting had minimal‐to‐no itch (change from baseline [CFB]: −1.8; p =...
ABSTRACT Pseudomonas aeruginosa is one of the major causative agents mortality and morbidity in hospitalized patients due to a multiplicity virulence factors associated with both chronic acute infections. Acute P. infection primarily mediated by planktonic bacteria expressing type III secretion system (TTSS), surface-attached needle-like complex that injects cytotoxins directly into eukaryotic cells, causing cellular damage. Lipopolysaccharide (LPS) principal surface-associated factor . This...
Increased plasminogen activator inhibitor-1 (PAI-1) concentrations are found in bronchoalveolar lavage (BAL) fluids from patients with ventilator-associated pneumonia or acute respiratory distress syndrome. The authors hypothesized that PAI-1 were associated increased mortality either Pseudomonas aeruginosa-induced tracheobronchial colonization.In a prospective cohort study, daily aspirates intubated cultured for P. aeruginosa. Positive had blind BAL (bBAL) was processed biomarker...
Examine relationships between the systemic exposure of acalabrutinib, a highly selective, next-generation Bruton tyrosine kinase inhibitor, and its active metabolite (ACP-5862) vs. efficacy safety responses in patients with B-cell malignancies who received acalabrutinib as monotherapy or combination obinutuzumab.For exposure-efficacy analyses, untreated chronic lymphocytic leukaemia were assessed for best overall response, progression-free survival tumour regression. For exposure-safety...
8064 Background: Acala is a next-generation, highly selective, covalent Bruton tyrosine kinase inhibitor approved in the US for patients (pts) with chronic lymphocytic leukemia (CLL)/small lymphoma (SLL) and previously treated mantle cell (MCL). We evaluated safety profile of acala monotherapy (monotx) multiple B malignancies. Methods: Data from pts activated B-cell diffuse large lymphoma, CLL, follicular MCL, myeloma, prolymphocytic leukemia, Richter syndrome, SLL, or Waldenström...
ABSTRACT Bacterial gene islands add to the genetic repertoire of opportunistic pathogens. Here, we perform comparative analyses three Pseudomonas aeruginosa strains isolated sequentially over a 3-week period from patient with ventilator-associated pneumonia (VAP) who received clindamycin and piperacillin-tazobactam as part their treatment regime. While all appeared be clonal by standard pulsed-field gel electrophoresis, whole-genome sequencing revealed subtle alterations in chromosomal...
Background: Health coaching programs, delivered by trained non-medical and medical personnel, focused on diet lifestyle counseling, have proven beneficial in both primary secondary prevention of cardiovascular disease. These however, not been tested or validated South Asians, who unique dietary habits, greatly increased risk coronary artery Methods: We examined lipid values participants were invited to enroll the Heart Coaching Program at Asian Center El Camino Hospital Mountain View,...
Abstract Background: Acalabrutinib is a selective BTK inhibitor approved for the treatment of Mantle Cell Lymphoma. Relationship between plasma exposures to acalabrutinib and ACP-5862 versus clinical efficacy safety were evaluated in subjects with B-cell malignancies, following administration monotherapy or combination obinutuzumab. Methods: (AUC24h,ss) generated using population pharmacokinetic (PK) analysis. To account contribution overall activity, an exposure metric (total active...